Fate Therapeutics, Inc.

NasdaqGM:FATE Stok Raporu

Piyasa değeri: US$260.8m

Fate Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Fate Therapeutics şirketinin kazançları yıllık ortalama -9.8% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında artan oldu. Gelirler yıllık ortalama 19.9% oranında artan oldu.

Anahtar bilgiler

-9.8%

Kazanç büyüme oranı

-3.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı19.9%
Özkaynak getirisi-49.2%
Net Marj-1,325.4%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Nov 20

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Aug 21
Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Aug 11
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 23
Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Feb 16
Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Jan 26

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Dec 19
Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Sep 08
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Jun 07
Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

May 08
Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Apr 17
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Sep 22
Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Aug 30

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Jul 28

Fate Therapeutics names Brian Powl as chief commercial officer

Jun 30

Fate: Possible Speedy FDA Approval Process With RMAT Designation

Jun 03

We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Jun 02
We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Fate Therapeutics: Slowly Getting To An Attractive Position

Feb 21

We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Feb 01
We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Gelir ve Gider Dağılımı

Fate Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGM:FATE Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 2413-178750
30 Jun 2412-176730
31 Mar 246-190780
31 Dec 2364-161790
30 Sep 23106-173850
30 Jun 23119-212880
31 Mar 23137-235850
31 Dec 2296-282840
30 Sep 2269-294800
30 Jun 2268-254740
31 Mar 2263-233660
31 Dec 2156-212570
30 Sep 2155-197510
30 Jun 2148-212430
31 Mar 2140-185390
31 Dec 2031-173340
30 Sep 2018-149300
30 Jun 2013-117280
31 Mar 2011-112260
31 Dec 1911-98240
30 Sep 1910-86210
30 Jun 198-76190
31 Mar 196-72180
31 Dec 185-67160
30 Sep 184-63150
30 Jun 184-57140
31 Mar 184-47120
31 Dec 174-43120
30 Sep 174-38110
30 Jun 174-36110
31 Mar 174-35100
31 Dec 164-33100
30 Sep 164-33100
30 Jun 164-31100
31 Mar 164-30100
31 Dec 152-30100
30 Sep 151-29100
30 Jun 150-2890
31 Mar 150-2790
31 Dec 140-2680
30 Sep 140-2580
30 Jun 140-2580
31 Mar 140-2480
31 Dec 131-2170

Kaliteli Kazançlar: FATE şu anda kârlı değil.

Büyüyen Kar Marjı: FATE şu anda kârlı değil.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: FATE kârlı değildir ve zararlar son 5 yılda yılda 9.8% oranında artmıştır.

Büyüme Hızlandırma: FATE 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: FATE kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.


Özkaynak Getirisi

Yüksek ROE: FATE hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -49.19% ) sahiptir.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin